+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Kymriah"

Acute Lymphoblastic Leukemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Thumbnail Image

Acute Lymphoblastic Leukemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • May 2024
  • 133 Pages
  • Global
From
Leukemia Therapeutics Market by Type (CLL, ALL, CML, AML), Treatment Type (Chemotherapy & Targeted Drugs), Mode of Administration (Oral, Injectable), Molecule Type (Small Molecules, Biologics), Gender, and Region - Global Forecast to 2024 - Product Thumbnail Image

Leukemia Therapeutics Market by Type (CLL, ALL, CML, AML), Treatment Type (Chemotherapy & Targeted Drugs), Mode of Administration (Oral, Injectable), Molecule Type (Small Molecules, Biologics), Gender, and Region - Global Forecast to 2024

  • Report
  • May 2019
  • 126 Pages
  • Global
From
Acute Lymphocytic Leukemia (ALL) - Market Insight, Epidemiology and Market Forecast - 2032 - Product Thumbnail Image

Acute Lymphocytic Leukemia (ALL) - Market Insight, Epidemiology and Market Forecast - 2032

  • Report
  • March 2024
  • 257 Pages
  • Global
From
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL) - Market Insight, Epidemiology and Market Forecast - 2032 - Product Thumbnail Image

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL) - Market Insight, Epidemiology and Market Forecast - 2032

  • Report
  • March 2024
  • 174 Pages
  • Global
From
CAR T-Cell Therapy Market, By Type (Abecma, Breyanzi, Kymriah, Tecartus, Yescarta), End-user (Hospitals, Specialty Clinics, Others), Application (Cancer, Lymphoma, Others), Region (North America, Europe, Asia Pacific, RoW) - Global Forecast to 2028 - Product Thumbnail Image

CAR T-Cell Therapy Market, By Type (Abecma, Breyanzi, Kymriah, Tecartus, Yescarta), End-user (Hospitals, Specialty Clinics, Others), Application (Cancer, Lymphoma, Others), Region (North America, Europe, Asia Pacific, RoW) - Global Forecast to 2028

  • Report
  • June 2022
  • 220 Pages
  • Global
From
Kymriah - Product Thumbnail Image

Kymriah

  • Report
  • January 2019
  • 38 Pages
  • Global
From
  • 6 Results (Page 1 of 1)
Loading Indicator

Kymriah is a type of leukemia drug that is used to treat certain types of cancer. It is a type of chimeric antigen receptor (CAR) T-cell therapy, which is a type of immunotherapy. Kymriah works by reprogramming a patient's own immune cells to recognize and attack cancer cells. It is approved for the treatment of certain types of B-cell acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). Kymriah is a relatively new type of cancer treatment, and the market for it is still developing. It is a personalized therapy, meaning that it is tailored to each individual patient. As such, it is more expensive than traditional chemotherapy treatments. However, it has been shown to be more effective in some cases. The Kymriah market is made up of a number of companies, including Novartis, Kite Pharma, Gilead Sciences, and Juno Therapeutics. These companies are involved in the research, development, and production of Kymriah. They are also involved in the marketing and distribution of the drug. Show Less Read more